Spectral AI Inc

Spectral AI Inc (MDAI) Stock Analysis

$1.495

+0.125 (+8.33%)At close

Loading chart…
High
1.530
Open
1.410
VWAP
1.47
Volume
166.46K
Mkt Cap
31.47M
Low
1.400
Amount
245.53K
EV/EBITDA, TTM
-1.19

Spectral AI, Inc. is a predictive artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns. The Company's DeepView platform is a predictive device that offers clinicians an objective and immediate assessment of a wound healing potential prior to treatment or other medical intervention. DeepView platform that combines AI algorithms and multispectral imaging (MSI) imaging for an assessment of wound healing potential. It is non-invasive, non-radiation, non-laser and does not require the use of injectable dye. The DeepView AI- Burn software is used with the DeepView SnapShot imaging device, and it is intended to be used as an adjunctive tool to aid healthcare providers in the assessment of burn wound healing potential by differentiating non-healing from healing burned tissue within an image.

AI analysis of Spectral AI Inc (MDAI)

Buy

Spectral AI Inc is a good buy right now due to its recent FDA clearance for the DeepView System, which is expected to drive revenue growth, with an anticipated revenue of approximately $18.5 million for the year. The current price is $1.52, significantly below the analyst price target of $4, indicating a potential upside of 163.16%. However, the company has a high forward P/E of 52.36, indicating potential valuation concerns as it continues to navigate operational losses.

Valuation Metrics

The current forward P/E ratio for Spectral AI Inc (MDAI) is 52.36, compared to its 5-year average forward P/E of 6.80.

Forward P/E

Strongly Overvalued
5Y Average P/E
6.80
Current P/E
52.36
Overvalued
25.58
Undervalued
-11.98

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
-18.84
Current EV/EBITDA
-1.19
Overvalued
3.75
Undervalued
-41.44

Forward P/S

Fair
5Y Average P/S
4.76
Current P/S
1.37
Overvalued
9.54
Undervalued
-0.02

Alphio AI Price Scenarios for MDAI

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%MDAI

$2.22

Scenario price

B

Base

Base · 50%MDAI

$2.20

Scenario price

B

Bear

Bear · 25%MDAI

$1.52

Scenario price

Events Timeline

2026-10-06 (ET)

09:00:00

Spectral AI Submits NTAP Application to CMS

2026-10-01 (ET)

09:00:00

Spectral AI Completes First Site Initiation Visit for Clinical Study

2026-07-08 (ET)

09:30:00

Spectral AI Appoints Darcy Bajko as Chief Commercial Officer

2026-05-26 (ET)

07:10:00

Spectral AI's DeepView System Receives FDA De Novo Classification

2026-04-08 (ET)

08:50:00

Spectral AI Appoints David McGuire as CFO

News

MDAI FAQ — answered by Alphio AI

Spectral AI, Inc. is a predictive artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns. The Company's DeepView platform is a predictive device that offers clinicians an objective and immediate assessment of a wound healing potential prior to treatment or other medical intervention. DeepView platform that combines AI algorithms and multispectral imaging (MSI) imaging for an assessment of wound healing potential. It is non-invasive, non-radiation, non-laser and does not require the use of injectable dye. The DeepView AI- Burn software is used with the DeepView SnapShot imaging device, and it is intended to be used as an adjunctive tool to aid healthcare providers in the assessment of burn wound healing potential by differentiating non-healing from healing burned tissue within an image. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Spectral AI Inc is a good buy right now due to its recent FDA clearance for the DeepView System, which is expected to drive revenue growth, with an anticipated revenue of approximately $18.5 million for the year. The current price is $1.52, significantly below the analyst price target of $4, indicating a potential upside of 163.16%. However, the company has a high forward P/E of 52.36, indicating potential valuation concerns as it continues to navigate operational losses.

Community

More ↗

No posts yet

Sign up or log in to join the discussion

Related articles

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Start trading